Thank you for the question. I'll make a couple of points.
Drug costs are borne by the employer, so any savings on the price of the medications will flow directly through to the employer and ultimately to the employee. It's sort of a pass-through cost, from our perspective. The savings there would accrue directly to Canadians.
If I may just comment quickly on one of the other elements I heard earlier, I think it is correct to say that there are pricing negotiations occurring within the public system with manufacturers, but those do not apply on the private side. One of the advantages of an approach that would apply to everyone, and one of the things we find attractive about this, is that PMPRB pricing does apply to all Canadians equally. This is an important piece for us.